[1]董丽,李彪.新生血管抑制剂人纤溶酶原kringle5的研究进展[J].国际放射医学核医学杂志,2008,32(2):69-71,78.
　DONG Li,LI Biao.Studying and progression of human plasminogen kringle 5[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):69-71,78.
点击复制

新生血管抑制剂人纤溶酶原kringle5的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
32
期数:
2008年第2期
页码:
69-71,78
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Studying and progression of human plasminogen kringle 5
作者:
董丽;  李彪
200025 上海, 上海交通大学附属瑞金医院核医学科
Author(s):
DONG Li;  LI Biao
Department of Nuclear Medicine, Shanghai Ruijin Hospital Affiliated Shanghai Jiaotong University, Shanghai 200025, China
关键词:
纤维蛋白溶酶原; 血管生成抑制剂; 肿瘤辅助疗法
Keywords:
Plasminogen; Angiogenesis inhibitors; Neoadjuvant therapy
摘要:
新生血管对于肿瘤的的生长、浸润和转移具有重要的意义,当瘤体体积超过1~2mm3时就需要新生血管提供营养维持代谢,同时提供转移通路。人纤溶酶原kringle5作为一种血管生成抑制因子,能够与新生血管的内皮细胞特异性结合,通过抑制新生血管内皮细胞增殖而减少新生血管的形成,因此在肿瘤新生血管靶向性治疗中具有很大的应用前景。利用核素标记人纤溶酶原kringle5对多种肿瘤及其转移病灶进行显像的同时实施内照射治疗,这一独特的肿瘤诊疗方法将受到人们的重视。
Abstract:
Neovascularization plays an important role in the processes of growth, invasion and metastasis in tumors. Solid tumors rely on neovaseularization to get oxygen and other nutrients supply, otherwise they are not able to expand over 1~2mm3. Meanwhile angiogenesis offers the pathway for metastasis. Hence, inhibitars of angiogenesis become the promise in the therapeutic research. Plasminogen kringle 5 is a proteolytic fragment of plasminogen. Inhibit proliferating vascular endothelial cells but also can induce apoptosis. These results suggest that the anti-angiogenic activity of kringle 5 shows its promising future in cancer therapy. The certain radiopharmaceuticals can be used to perform both imaging and internal radiotherapy in many kinds of carcinomas, in both original and metastatic sites. This unique method will catch our eyes dramatically.

参考文献/References:

[1] Lu H, Dhanabal M, Volk R, et al. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells[J]. Binchem Biophys Res Commun, 1999, 258(3):668-673.
[2] Cai W, Ma J, Li C, et al. Enhanced anti-angiogenic effect of a deletion mutant of plasminogen kringle 5 on neovascularization[J]. J Cell Biochem, 2005:96(6):1254-1261.
[3] Léger R, Benquet C, Huang X, et al. Kringle 5 peptide-albumin conjugates with anti-migratory activity[J]. Bioorg Med Chem Lett, 2004, 14(4):841-845.
[4] Nguyen TM, Subramanian IV, Kelekar A, et al. Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells[J]. Blood, 2007, 109(11):4793-4802.
[5] Wang H, Schultz R, Hong Y, et al. Cell surface-dependent generation of angiostatin4.5[J]. Cancer Res, 2004, 64(1):162-168.
[6] Griffioen AW, Molema G. Angiogenesis:potentials for pharmacologic interventioa in the treatment of cancer, cardiovascular diseases, and chronic inflammation[J]. Pharmacol Rev, 2000, 52(2):237-268.
[7] Wang H, Doll JA, Jiang K, et al. Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin:implications for cancer-mediated angiogenesis[J]. Cancer Res, 2006, 66(14):7211-7215.
[8] Gonzalez-Gronow M, Kalfa T, Johnson CE, et al. The vohagedependent anion channel is a receptor for plasminogen kringle 5 on human endothelial cells[J]. J Biol Chem, 2003, 278(29):27312-27318.
[9] Gao G, Li Y, Gee S, et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor:a possible mechanism for the anti-angiogenic activity of plasminogen kringle5[J]. J Biol Chem, 2002, 277(11):9492-9497.
[10] Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3)in endothelial cells[J]. J Biol Chem, 2001,276(43):39562-39568.
[11] Davidson DJ, Haskell C, Majest S, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78[J]. Cancer Res, 2005, 65(11):4663-4672.
[12] Yang X, Cheng R, Li C, et al. Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity[J]. Cancer Biol Ther, 2006, 5(4):399-405.
[13] Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents:exploring mechanisms of interaction[J]. Clin Cancer Res, 2003, 9(6):1957-1971.
[14] 李彪,赵龙,张一帆,等.重组人纤溶酶原Kringle5的标记及其肿瘤显像[J].上海第二医科大学学报,2005,25(12):1218-1220.
[15] 尹桂芝,李彪,张大东,等.重组人纤溶酶原Kringle 5的125I标记及其体内代谢[J].黑龙江医药科学,2007,30(1):51-53.

相似文献/References:

[1]杨坤禹,胡豫.抗肿瘤血管新生联合放射治疗研究进展[J].国际放射医学核医学杂志,2006,30(2):122.
　YANG Kun-yu,HU Yu.The progress on anti-angiogenesis combined with radiotherapy in malignancies[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):122.

备注/Memo

备注/Memo:
收稿日期:2007-09-16。
通讯作者:李彪(E-mail:biaoli63@hotmail.com)
更新日期/Last Update: 1900-01-01